Distinct Types of Primary Cutaneous Large B-cell Lymphoma Identified by Gene Expression Profiling
Overview
Authors
Affiliations
In the European Organization for Research and Treatment of Cancer (EORTC) classification 2 types of primary cutaneous large B-cell lymphoma (PCLBCL) are distinguished: primary cutaneous follicle center cell lymphomas (PCFCCL) and PCLBCL of the leg (PCLBCL-leg). Distinction between both groups is considered important because of differences in prognosis (5-year survival > 95% and 52%, respectively) and the first choice of treatment (radiotherapy or systemic chemotherapy, respectively), but is not generally accepted. To establish a molecular basis for this subdivision in the EORTC classification, we investigated the gene expression profiles of 21 PCLBCLs by oligonucleotide microarray analysis. Hierarchical clustering based on a B-cell signature (7450 genes) classified PCLBCL into 2 distinct subgroups consisting of, respectively, 8 PCFCCLs and 13 PCLBCLsleg. PCLBCLs-leg showed increased expression of genes associated with cell proliferation; the proto-oncogenes Pim-1, Pim-2, and c-Myc; and the transcription factors Mum1/IRF4 and Oct-2. In the group of PCFCCL high expression of SPINK2 was observed. Further analysis suggested that PCFCCLs and PCLBCLs-leg have expression profiles similar to that of germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphoma, respectively. The results of this study suggest that different pathogenetic mechanisms are involved in the development of PCFCCLs and PCLBCLs-leg and provide molecular support for the subdivision used in the EORTC classification.
Cao X, Luo N, Liu X, Guo K, Deng M, Lv C Onco Targets Ther. 2025; 18:161-177.
PMID: 39926372 PMC: 11806753. DOI: 10.2147/OTT.S487126.
Martinez-Banaclocha N, Martinez-Madueno F, Caballe B, Badia J, Blanes M, Bujanda D Cancers (Basel). 2024; 16(5).
PMID: 38473391 PMC: 10931196. DOI: 10.3390/cancers16051034.
Guo Y, Chai B, Zhang H, Chai X, Chen Y, Xu J Biol Direct. 2024; 19(1):15.
PMID: 38388961 PMC: 10885466. DOI: 10.1186/s13062-024-00459-0.
IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies.
Parrondo R, Iqbal M, von Roemeling R, von Roemeling C, Tun H Front Immunol. 2023; 14:1239082.
PMID: 37954584 PMC: 10637517. DOI: 10.3389/fimmu.2023.1239082.
Yuan Y, Shi Q, He Y, Qiu H, Yi H, Dong L Zhonghua Xue Ye Xue Za Zhi. 2023; 44(8):690-693.
PMID: 37803847 PMC: 10520235. DOI: 10.3760/cma.j.issn.0253-2727.2023.08.015.